Friday, October 5, 2012

Antibody drug maker KaloBios seeks $60M IPO

David Pritchard.
KaloBios Pharmaceuticals Inc. seeks to raise $60 million in an initial public offering, the company said Friday. It is the second IPO by a Bay Area life sciences company in the past week. Heart disease test maker Singulex Inc. filed Sept. 28 for an $86 million IPO. The IPO from South San Francisco's KaloBios, which makes disease-fighting antibodies, comes as no surprise. As the company brought on Jeff Cooper this summer as its first chief financial officer, President and CEO David Pritchard told the San Francisco Business Times that he expected to file IPO paperwork sometime over the next 12 months.

1 comment:

  1. i was looking for this type of stuff from last days.
    Antibody Conjugate